Non-Viral Gene Delivery Technologies Market Report 2025

The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $3.96 billion in 2024 to $4.57 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth during the historic period can be attributed to the expansion of genetic research, the rising prevalence of chronic genetic disorders, increasing biotechnology and pharmaceutical R\&D activities, advancements in genetic and molecular biology research, and greater government and institutional funding.

The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $8.06 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to the rising demand for personalized medicine, increasing adoption in cancer and rare disease research, the advancement of CRISPR and other gene editing technologies, rapid expansion of mRNA-based therapeutics, and the continued growth of cell therapy and tissue engineering. Key trends expected during this period include advancements in lipid nanoparticles and polymer-based vectors, the development of DNA- and RNA-based therapeutics, integration with artificial intelligence and computational modeling, the emergence of next-generation lipid nanoparticles (LNPs), and continued progress in nanotechnology.

The rising demand for personalized medicine is expected to drive the growth of the non-viral gene delivery technologies market in the coming years. Personalized medicine is a healthcare approach that tailors prevention, diagnosis, and treatment to an individual’s unique genetic makeup, lifestyle, and environmental factors. This growing demand is fueled by advances in genomic sequencing technologies, which enable more precise diagnoses, targeted therapies, and improved treatment outcomes customized to each patient. Non-viral gene delivery technologies play a key role in this trend, as they provide safer and more flexible methods for delivering therapeutic genes based on a patient’s genetic profile, without the safety risks associated with viral vectors. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases in 2023, compared with 6 approvals in 2022. Therefore, the growing adoption of personalized medicine is fueling the demand for non-viral gene delivery technologies.

Companies in the non-viral gene delivery market are also advancing innovations such as non-viral genetic medicine platforms to improve the safety and precision of gene therapies. These platforms deliver therapeutic genes or nucleic acids into cells without using viruses, lowering the risk of immune responses and other safety concerns while enabling controlled and accurate gene therapy for various diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company, introduced immune-quiet DNA (iqDNA), an enhanced version of its closed-ended DNA (ceDNA). This novel DNA avoids innate immune system detection and demonstrated cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered through its lipid nanoparticle (LNP) system. Due to its improved safety profile, Generation Bio is prioritizing iqDNA as the main DNA cargo across its programs, including its lead hemophilia A treatment.

In September 2023, SOHM Inc., a US-based pharmaceutical company specializing in generic and private-label drugs, acquired ABBIE Inc. for an undisclosed sum. This acquisition strengthens SOHM’s position in non-viral gene delivery technologies, enhancing its capacity to develop next-generation gene-editing solutions and expand its footprint in the genetic therapeutics market. ABBIE Inc. is a US-based gene-editing platform company that develops non-viral vector-based delivery systems for genetic payloads.

Major players in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Boehringer Ingelheim GmbH, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corp., Takara Bio Inc., GenScript Biotech Corporation, Poseida Therapeutics Inc., ElevateBio LLC, ProBio Inc., ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

North America was the largest region in the non-viral gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-viral gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the non-viral gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Non-viral gene delivery technologies are approaches for transferring genetic material into cells without relying on viruses as carriers. These methods reduce safety risks and immune responses associated with viral systems while allowing for precise and controlled delivery. Their primary purpose is to modify or regulate gene expression for the treatment of genetic disorders and the advancement of cell-based therapies.

The main product categories in non-viral gene delivery technologies include reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are ready-to-use chemical formulations designed to introduce genetic material into cells without the use of viruses. Delivery can be achieved through various modes, such as in vitro, in vivo, and ex vivo, using technologies like electroporation, lipid-based transfection, polymer-based transfection, physical methods (e.g., microinjection and gene gun), and nanoparticles. These technologies have applications in gene therapy, DNA vaccines, RNA interference (RNAi), CRISPR/Cas9 gene editing, and protein expression. End users include biotechnology and biopharmaceutical companies, research and academic institutes, and others.

The non-viral gene delivery technologies market research report is one of a series of new reports that provides non-viral gene delivery technologies market statistics, including non-viral gene delivery technologies industry global market size, regional shares, competitors with a non-viral gene delivery technologies market share, detailed non-viral gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. The non-viral gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.